Bone Biologics (BBLG) Debt Ratio (2014 - 2019)

Bone Biologics (BBLG) posted quarterly Debt Ratio of 367.21 for Q4 2019, up 9489.51% quarter-over-quarter from 3.83 in Q3 2018.

Analysis

Bone Biologics (BBLG) Debt Ratio (2014 - 2019) Analysis & Trends

Bone Biologics (BBLG) has reported Debt Ratio for 7 consecutive years, with 367.21 the latest figure, recorded in Q4 2019.

In Q4 2019, Debt Ratio changed N/A year-over-year to 367.21; the TTM figure through Dec 2019 stood at 367.21 (changed N/A YoY), while the FY2019 annual figure was 367.21, changed N/A from the prior year.
Debt Ratio grew to 367.21 in Q4 2019 per BBLG's latest filing, from 3.83 in the prior quarter.
Across five years, Debt Ratio topped out at 367.21 in Q4 2019 and bottomed at 1.17 in Q1 2015.
Historically, Debt Ratio has averaged 32.72 across 5 years, with a median of 10.71 in 2017.
Annual changes were most pronounced in 2016 — Debt Ratio soared 414.74% — and 2018, when it sank 68.22%.
Bone Biologics' Debt Ratio stood at 7.81 in 2015, then jumped by 60.0% to 12.5 in 2016, then retreated by 17.24% to 10.34 in 2017, then slumped by 62.98% to 3.83 in 2018, then jumped by 9489.51% to 367.21 in 2019.
Business Quant data shows BBLG's Debt Ratio at 367.21 in Q4 2019, 3.83 in Q3 2018, and 22.67 in Q2 2018.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	141.52 Bn	133.66 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.69 Bn	78.69 Bn	3.93 Bn	0.05
3	Argenx Se	64.63 Bn	59.45 Bn	1.37 Bn	-
4	Moderna	59.30 Bn	54.16 Bn	52.00 Mn	0.05
5	Revolution Medicines	44.41 Bn	44.41 Bn	-	-
6	BeOne Medicines	40.45 Bn	35.35 Bn	1.53 Bn	0.12
7	Alnylam Pharmaceuticals	35.29 Bn	31.98 Bn	992.69 Mn	-
8	Royalty Pharma	28.44 Bn	27.60 Bn	-	0.47
9	Insmed	27.55 Bn	26.39 Bn	358.27 Mn	0.26
10	Bone Biologics	1.00 Mn	1.00 Mn	-	-

Historic Data

Download Data